- Title
- InforMing the PAthway of COPD Treatment Single-Inhaler Triple Therapy (Fluticasone Furoate/ Umeclidinium/ Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium /Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions
- Creators - without role
- Arnaud Bourdin - Université de Montpellier, Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExpGerard Criner - Temple UniversityGilles Devouassoux - Université Claude Bernard Lyon 1Mark Dransfield - University of Alabama at BirminghamDavid M.G. Halpin - University of ExeterMeilan Han - University of Michigan–Ann ArborC. Elaine Jones - TriangleRavi Kalhan - Northwestern UniversityPeter Lange - University of CopenhagenSally Lettis - GlaxoSmithKlineDavid Lipson - University of PennsylvaniaDavid Lomas - University College LondonJosé Echave-Sustaeta María-Tomé - Hospital Universitario Quirónsalud MadridNeil Martin - GlaxoSmithKlineFernando Martinez - Cornell UniversityHolly Quasny - Research Triangle Park FoundationLynda Sail - GlaxoSmithKlineThomas Siler - Midwest Chest Consultants, PC, St Charles, MissouriDave Singh - University of ManchesterByron Thomashow - Columbia University Irving Medical CenterHenrik Watz - German Center for Lung ResearchRobert Wise - Johns Hopkins MedicineNicola Hanania - Baylor College of Medicine
- Publication Details
- Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Identifiers
- 9939422109311
- Academic Unit
- Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
- Language
- English
- Resource Type
- Journal article
- Local Fields
- hal-02995478
Journal article
InforMing the PAthway of COPD Treatment Single-Inhaler Triple Therapy (Fluticasone Furoate/ Umeclidinium/ Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium /Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions
Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
2020
Metrics
1 Record Views